Core Insights - The flow cytometer industry in China is projected to reach a market size of approximately 3.599 billion yuan in 2024, reflecting a year-on-year growth of 19.21% [1][9] - The industry is achieving systematic breakthroughs along three main paths: expanding detection limits, enhancing analytical dimensions, and integrating functional platforms [1][9] Industry Overview - Flow cytometers utilize lasers to detect scattered light and fluorescence signals from cells or particles in a high-speed flow state, enabling rapid multi-parameter analysis, sorting, and quantitative characterization [2] - The core principle involves hydrodynamic focusing technology that allows cells to pass through the laser detection area in a single file, capturing forward scatter (indicating cell size), side scatter (indicating internal complexity), and fluorescence signals [2] Industry Development History - The flow cytometer industry in China has evolved over 40 years, starting with the introduction of the first FACS III in 1981, leading to significant milestones in domestic production and technology breakthroughs from 2013 onwards [4] - Key advancements include the introduction of the first clinical spectral flow cytometer and the first flow mass spectrometer with IVD registration, marking significant progress in high-end equipment [4] Market Size - The flow cytometer market is experiencing a shift from laboratory to clinical applications, with a notable increase in market size and technological advancements [9] - Noteworthy innovations include the development of nano-flow technology by Fuliu Biotechnology, which extends detection limits to 24nm, and the NL-CLC spectral flow cytometer by Xiatai Biotechnology, the first clinical-approved full-spectrum product in China [9] Key Companies - Major players in the flow cytometer market include Mindray Medical, which has integrated instruments, reagents, and software into a comprehensive platform, and Fuliu Biotechnology, a leader in nano-flow technology [10][11] - Mindray's revenue for the first three quarters of 2025 was 25.834 billion yuan, a decrease of 12.38% year-on-year, with a net profit of 7.570 billion yuan, down 28.83% [11] Industry Trends - The industry is witnessing accelerated technological iteration, with a focus on high-end and intelligent advancements, including the integration of AI for data analysis and high-throughput sorting [12] - Applications are expanding beyond clinical and research fields into broader industrial and public health areas, such as environmental monitoring and food safety [13] - The domestic production process is accelerating, driven by supply chain security and the need for local alternatives, reshaping the competitive landscape [14]
研判2025!中国流式细胞仪行业发展历程、产业链及市场现状分析:流式细胞仪驱动生命科学向临床转化,纳米级检测开拓外泌体新场景[图]